Skip to main content
NASDAQ:PPD

PPD Competitors

$46.14
+0.06 (+0.13 %)
(As of 05/13/2021 11:09 AM ET)
Add
Compare
Today's Range
$46.11
$46.16
50-Day Range
$36.62
$46.29
52-Week Range
$24.75
$46.49
Volume83,770 shs
Average Volume2.57 million shs
Market Capitalization$16.19 billion
P/E Ratio307.60
Dividend YieldN/A
BetaN/A

Competitors

PPD (NASDAQ:PPD) Vs. IQV, INCY, EXAS, CRL, ICLR, and PRAH

Should you be buying PPD stock or one of its competitors? Companies in the industry of "commercial physical research" are considered alternatives and competitors to PPD, including IQVIA (IQV), Incyte (INCY), Exact Sciences (EXAS), Charles River Laboratories International (CRL), ICON Public (ICLR), and PRA Health Sciences (PRAH).

PPD (NASDAQ:PPD) and IQVIA (NYSE:IQV) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.

Profitability

This table compares PPD and IQVIA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PPD0.21%-11.06%2.75%
IQVIA1.61%18.03%4.64%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for PPD and IQVIA, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PPD012302.20
IQVIA011502.94

PPD presently has a consensus target price of $43.3636, indicating a potential downside of 6.02%. IQVIA has a consensus target price of $243.8333, indicating a potential upside of 5.84%. Given IQVIA's stronger consensus rating and higher possible upside, analysts clearly believe IQVIA is more favorable than PPD.

Insider and Institutional Ownership

68.8% of PPD shares are owned by institutional investors. Comparatively, 87.2% of IQVIA shares are owned by institutional investors. 6.0% of IQVIA shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares PPD and IQVIA's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PPD$4.03 billion4.02$47.82 million$0.9847.08
IQVIA$11.09 billion3.98$191 million$5.9438.79

IQVIA has higher revenue and earnings than PPD. IQVIA is trading at a lower price-to-earnings ratio than PPD, indicating that it is currently the more affordable of the two stocks.

Summary

IQVIA beats PPD on 11 of the 13 factors compared between the two stocks.

Incyte (NASDAQ:INCY) and PPD (NASDAQ:PPD) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent recommendations for Incyte and PPD, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Incyte18802.41
PPD012302.20

Incyte presently has a consensus price target of $99.50, indicating a potential upside of 20.88%. PPD has a consensus price target of $43.3636, indicating a potential downside of 6.02%. Given Incyte's stronger consensus rating and higher probable upside, equities analysts plainly believe Incyte is more favorable than PPD.

Profitability

This table compares Incyte and PPD's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Incyte-13.62%-13.66%-9.98%
PPD0.21%-11.06%2.75%

Earnings and Valuation

This table compares Incyte and PPD's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Incyte$2.16 billion8.39$446.91 million$2.2336.91
PPD$4.03 billion4.02$47.82 million$0.9847.08

Incyte has higher earnings, but lower revenue than PPD. Incyte is trading at a lower price-to-earnings ratio than PPD, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

91.4% of Incyte shares are held by institutional investors. Comparatively, 68.8% of PPD shares are held by institutional investors. 16.1% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Incyte beats PPD on 8 of the 13 factors compared between the two stocks.

PPD (NASDAQ:PPD) and Exact Sciences (NASDAQ:EXAS) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Profitability

This table compares PPD and Exact Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PPD0.21%-11.06%2.75%
Exact Sciences-25.27%-11.71%-6.74%

Insider & Institutional Ownership

68.8% of PPD shares are held by institutional investors. Comparatively, 90.4% of Exact Sciences shares are held by institutional investors. 1.8% of Exact Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for PPD and Exact Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PPD012302.20
Exact Sciences031202.80

PPD presently has a consensus price target of $43.3636, indicating a potential downside of 6.02%. Exact Sciences has a consensus price target of $154.20, indicating a potential upside of 63.33%. Given Exact Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Exact Sciences is more favorable than PPD.

Valuation & Earnings

This table compares PPD and Exact Sciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PPD$4.03 billion4.02$47.82 million$0.9847.08
Exact Sciences$876.29 million18.48$-83,990,000.00($1.49)-63.36

PPD has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than PPD, indicating that it is currently the more affordable of the two stocks.

Summary

PPD beats Exact Sciences on 7 of the 13 factors compared between the two stocks.

PPD (NASDAQ:PPD) and Charles River Laboratories International (NYSE:CRL) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Profitability

This table compares PPD and Charles River Laboratories International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PPD0.21%-11.06%2.75%
Charles River Laboratories International10.68%22.41%7.66%

Analyst Ratings

This is a breakdown of current ratings and price targets for PPD and Charles River Laboratories International, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PPD012302.20
Charles River Laboratories International03902.75

PPD currently has a consensus target price of $43.3636, indicating a potential downside of 6.02%. Charles River Laboratories International has a consensus target price of $286.4167, indicating a potential downside of 10.45%. Given PPD's higher possible upside, research analysts plainly believe PPD is more favorable than Charles River Laboratories International.

Insider and Institutional Ownership

68.8% of PPD shares are held by institutional investors. Comparatively, 92.3% of Charles River Laboratories International shares are held by institutional investors. 1.9% of Charles River Laboratories International shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares PPD and Charles River Laboratories International's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PPD$4.03 billion4.02$47.82 million$0.9847.08
Charles River Laboratories International$2.62 billion6.13$252.02 million$6.7347.52

Charles River Laboratories International has lower revenue, but higher earnings than PPD. PPD is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Summary

Charles River Laboratories International beats PPD on 10 of the 13 factors compared between the two stocks.

PPD (NASDAQ:PPD) and ICON Public (NASDAQ:ICLR) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Valuation & Earnings

This table compares PPD and ICON Public's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PPD$4.03 billion4.02$47.82 million$0.9847.08
ICON Public$2.81 billion4.29$373.99 million$6.8832.59

ICON Public has lower revenue, but higher earnings than PPD. ICON Public is trading at a lower price-to-earnings ratio than PPD, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

68.8% of PPD shares are owned by institutional investors. Comparatively, 81.7% of ICON Public shares are owned by institutional investors. 44.0% of ICON Public shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for PPD and ICON Public, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PPD012302.20
ICON Public03702.70

PPD presently has a consensus price target of $43.3636, suggesting a potential downside of 6.02%. ICON Public has a consensus price target of $236.00, suggesting a potential upside of 5.25%. Given ICON Public's stronger consensus rating and higher probable upside, analysts plainly believe ICON Public is more favorable than PPD.

Profitability

This table compares PPD and ICON Public's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PPD0.21%-11.06%2.75%
ICON Public11.95%21.42%11.85%

Summary

ICON Public beats PPD on 11 of the 13 factors compared between the two stocks.

PRA Health Sciences (NASDAQ:PRAH) and PPD (NASDAQ:PPD) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and profitability.

Institutional and Insider Ownership

96.1% of PRA Health Sciences shares are owned by institutional investors. Comparatively, 68.8% of PPD shares are owned by institutional investors. 1.3% of PRA Health Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares PRA Health Sciences and PPD's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PRA Health Sciences7.09%22.21%7.04%
PPD0.21%-11.06%2.75%

Analyst Ratings

This is a summary of recent ratings for PRA Health Sciences and PPD, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PRA Health Sciences18102.00
PPD012302.20

PRA Health Sciences presently has a consensus price target of $145.00, suggesting a potential downside of 15.02%. PPD has a consensus price target of $43.3636, suggesting a potential downside of 6.02%. Given PPD's stronger consensus rating and higher probable upside, analysts plainly believe PPD is more favorable than PRA Health Sciences.

Earnings & Valuation

This table compares PRA Health Sciences and PPD's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PRA Health Sciences$3.07 billion3.61$243.02 million$4.8035.55
PPD$4.03 billion4.02$47.82 million$0.9847.08

PRA Health Sciences has higher earnings, but lower revenue than PPD. PRA Health Sciences is trading at a lower price-to-earnings ratio than PPD, indicating that it is currently the more affordable of the two stocks.

Summary

PRA Health Sciences beats PPD on 7 of the 13 factors compared between the two stocks.


PPD Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
IQVIA logo
IQV
IQVIA
1.7$230.39+1.0%$43.70 billion$11.09 billion253.18Analyst Report
Unusual Options Activity
Incyte logo
INCY
Incyte
1.6$82.31+0.1%$18.12 billion$2.16 billion-52.43Analyst Report
Exact Sciences logo
EXAS
Exact Sciences
2.0$94.41+1.8%$16.49 billion$876.29 million-42.72Analyst Report
News Coverage
Charles River Laboratories International logo
CRL
Charles River Laboratories International
1.3$319.83+1.0%$15.92 billion$2.62 billion53.31Insider Selling
Analyst Revision
ICON Public logo
ICLR
ICON Public
2.0$224.23+0.0%$12.03 billion$2.81 billion37.37Analyst Report
Analyst Revision
PRA Health Sciences logo
PRAH
PRA Health Sciences
1.6$170.63+0.3%$11.02 billion$3.07 billion49.89Analyst Downgrade
Analyst Revision
Syneos Health logo
SYNH
Syneos Health
1.6$85.12+0.2%$8.86 billion$4.68 billion46.77
Exelixis logo
EXEL
Exelixis
1.9$25.34+0.7%$7.88 billion$967.78 million52.79Earnings Announcement
Medpace logo
MEDP
Medpace
1.2$160.46+0.4%$5.79 billion$860.97 million49.07
Precigen logo
PGEN
Precigen
1.7$6.57+3.7%$1.41 billion$90.72 million-3.49Analyst Report
Insider Selling
Gap Up
National Research logo
NRC
National Research
0.8$49.16+2.5%$1.23 billion$127.98 million33.44Gap Up
Anavex Life Sciences logo
AVXL
Anavex Life Sciences
1.3$10.77+4.1%$723.42 millionN/A-23.93
Luna Innovations logo
LUNA
Luna Innovations
1.5$11.20+3.7%$338.78 million$70.52 million62.22Upcoming Earnings
Pieris Pharmaceuticals logo
PIRS
Pieris Pharmaceuticals
1.4$1.79+0.0%$113.31 million$46.28 million-3.38Upcoming Earnings
Gap Up
Eloxx Pharmaceuticals logo
ELOX
Eloxx Pharmaceuticals
1.2$1.73+2.9%$85.18 millionN/A-1.73Earnings Announcement
Cleveland BioLabs logo
CBLI
Cleveland BioLabs
0.6$4.51+0.4%$69.46 million$1.11 million0.00Gap Up
Tenax Therapeutics logo
TENX
Tenax Therapeutics
1.4$2.10+1.0%$31.44 millionN/A-1.74
AIkido Pharma logo
AIKI
AIkido Pharma
1.0$0.85+5.9%$29.79 million$10,000.000.00News Coverage
Gap Down
This page was last updated on 5/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.